Hepato-gastroenterology department Hospital Saint Joseph, 26 Bd de Louvain 13008 Marseilles France. Electronic address: firstname.lastname@example.org.
Hepato-gastroenterology department Hospital Saint Joseph, 26 Bd de Louvain 13008 Marseilles France.
The advent of oral direct-acting antiviral agents (DAAs) has dramatically improved hepatitis C treatment landscape in the last four years, providing cure rates over 95% with shorter duration of treatment and a very good safety profile. This allowed giving access to treatment in nearly all Hepatitis C virus (HCV) infected patients. The launch of two pangenotypic fixed dose combinations (FDC) in 2017 made a new step forward in hepatitis C treatment by slightly increasing efficacy and more importantly allowing to treat patients without HCV genotyping and in some cases without fibrosis assessment. New triple regimens have solved the issue of retreatment of the few patients who present failure to DAAs therapy. In the present review we describe the current HCV landscape that allows to cure nearly all HCV infected patients.